Literature DB >> 1348570

Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation.

Y G Xi1, L Ingrosso, A Ladogana, C Masullo, M Pocchiari.   

Abstract

Scrapie and related animal and human disorders are neurodegenerative diseases characterized by the formation of a modified, partly proteinase-resistant protein (PrP) of the host, which tends to aggregate as amyloid fibrils and accumulate in the brain of infected individuals. There is a general consensus that the pathological form of PrP (PrPSc) is essential for the clinical appearance of the disease, but whether it is part of the scrapie agent or a by-product of viral infection is still controversial. Here we report that treatment of scrapie-infected hamsters with amphotericin B delays the accumulation in the brain of the proteinase-resistant portion of PrPSc by about 30 days without affecting scrapie replication. The consequence is that hamsters treated with amphotericin B developed clinical signs of disease later than infected controls. We argue that the proteinase-resistant portion of PrPSc is necessary for the development of the disease but that it is unlikely to be essential for scrapie replication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348570     DOI: 10.1038/356598a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  41 in total

1.  Neuroinvasion by a Creutzfeldt-Jakob disease agent in the absence of B cells and follicular dendritic cells.

Authors:  M J Shlomchik; K Radebold; N Duclos; L Manuelidis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

2.  Virus-like interference in the latency and prevention of Creutzfeldt-Jakob disease.

Authors:  Laura Manuelidis; Zhi Yun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-11       Impact factor: 11.205

3.  Agent-specific Shadoo responses in transmissible encephalopathies.

Authors:  Kohtaro Miyazawa; Laura Manuelidis
Journal:  J Neuroimmune Pharmacol       Date:  2010-01-30       Impact factor: 4.147

4.  Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures.

Authors:  A Mangé; N Nishida; O Milhavet; H E McMahon; D Casanova; S Lehmann
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 5.  De novo mammalian prion synthesis.

Authors:  Federico Benetti; Giuseppe Legname
Journal:  Prion       Date:  2009-10-26       Impact factor: 3.931

6.  Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent.

Authors:  L Manuelidis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

7.  Early appearance but lagged accumulation of detergent-insoluble prion protein in the brains of mice inoculated with a mouse-adapted Creutzfeldt-Jakob disease agent.

Authors:  R Nakaoke; S Sakaguchi; R Atarashi; N Nishida; K Arima; K Shigematsu; S Katamine
Journal:  Cell Mol Neurobiol       Date:  2000-12       Impact factor: 5.046

Review 8.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Tetracyclines affect prion infectivity.

Authors:  Gianluigi Forloni; Selina Iussich; Tazeen Awan; Laura Colombo; Nadia Angeretti; Laura Girola; Ilaria Bertani; Giorgio Poli; Maria Caramelli; Maria Grazia Bruzzone; Laura Farina; Lucia Limido; Giacomina Rossi; Giorgio Giaccone; James W Ironside; Orso Bugiani; Mario Salmona; Fabrizio Tagliavini
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  Conserved features of intermediates in amyloid assembly determine their benign or toxic states.

Authors:  Rajaraman Krishnan; Jessica L Goodman; Samrat Mukhopadhyay; Chris D Pacheco; Edward A Lemke; Ashok A Deniz; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.